Eli Lilly is hiring new scientists to work on osteoporosis treatments, according to Bloomberg. Venture capitalists are now making bone health a priority after a long-awaited regulatory change incentivized the pharma industry to revisit the field.
What Osteoporosis Is
Osteoporosis is a condition that makes bones thin and fragile, affecting older adults. The disease causes bones to lose density and strength, which increases the risk of fractures.
The Four Big Players
Several major drugmakers have their own osteoporosis treatments:
- Eli Lilly
- Merck
- Novartis
- GSK
Each company has developed a treatment designed to stop bones from weakening.
Why the Drugs Stopped Working
The drugs required a burdensome approach to getting them into patients. Safety issues have kept many patients from taking treatments that could help them. As a result, many patients who are eligible for osteoporosis therapies don’t take any of the drugs available today.
Lilly’s Move
Eli Lilly is recruiting scientists to work on osteoporosis therapies. Other pharmaceutical companies are rumored to be following suit.
The VC Push
Venture capitalists, having taken notice of the regulatory change, are now making bone health one of their priorities. The move suggests that the field is on the move, and investors see an opening in osteoporosis.
The Regulatory Change
The long-awaited regulatory change has incentivized the pharma industry to revisit osteoporosis. The change is a factor, but it is not the only one. Companies are also looking at the market opportunity.
The Challenge Ahead
The story rests on a single Bloomberg report about Lilly’s hiring, a rumor about other companies, and one statement from a venture capitalist. The report does not provide data on actual new investment, trial activity, or market behavior.
What the Story Says
The story is a snapshot of a field that has been waiting for a signal. The regulatory change has given that signal, and companies are responding. The VC interest is a sign that money is looking at the space.
Two Sides of the Same Problem
| Factor | Direction |
|---|---|
| Drug requirements | Cumbersome, stunted use |
| Safety concerns | Reduced patient take-up |
| Regulatory change | Incentivized industry interest |
| VC investment | New priority |
The picture is mixed. There are real obstacles to overcome, and the report does not say how those obstacles will be met.
The Bottom Line
Osteoporosis drugs have a hard road ahead. The market opportunity exists, and the regulatory change has changed the calculation for companies. The evidence so far is limited to hiring reports and rumors.
See the a run of 37 images at STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.